Compare · ICCC vs NNNN
ICCC vs NNNN
Side-by-side comparison of ImmuCell Corporation (ICCC) and Anbio Biotechnology (NNNN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICCC and NNNN operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NNNN is the larger of the two at $2.48B, about 28.2x ICCC ($87.8M).
- Over the past year, ICCC is up 46.6% and NNNN is up 111.7% - NNNN leads by 65.1 points.
- NNNN has hit the wire 1 time in the past 4 weeks while ICCC has been quiet.
- Company
- ImmuCell Corporation
- Anbio Biotechnology
- Price
- $9.86-0.70%
- $18.23-34.52%
- Market cap
- $87.8M
- $2.48B
- 1M return
- +9.92%
- -30.41%
- 1Y return
- +46.62%
- +111.73%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1987
- 2025
- News (4w)
- 0
- 1
- Recent ratings
- 0
- 0
ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Latest ICCC
- ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by ImmuCell Corporation
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
- Amendment: SEC Form 10-K/A filed by ImmuCell Corporation
- ImmuCell Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
- SEC Form DEF 14A filed by ImmuCell Corporation
- SEC Form 3 filed by new insider Dimarco Anthony
- SEC Form 3 filed by new insider Guillemette Gilles
- SEC Form 4 filed by Turner Kathy V
Latest NNNN
- SEC Form 6-K filed by Anbio Biotechnology
- SEC Form 6-K filed by Anbio Biotechnology
- Amendment: SEC Form 20-F/A filed by Anbio Biotechnology
- SEC Form 3 filed by new insider Song Suki
- SEC Form 3 filed by new insider Hartzler Nancy
- SEC Form 3 filed by new insider Lau Michael
- SEC Form 3 filed by new insider Tian Chris
- SEC Form 3 filed by new insider Xu Cany
- SEC Form 20-F filed by Anbio Biotechnology
- Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum